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Abstract
Objectives: Interleukin- 1 (IL-1) is a multifunctional proinflammatory cytokine. There have been
studies suggesting a role in affecting growth and invasiveness of malignant breast cells by either
blocking or stimulating growth of cultured MCF-7 breast cancer cells. This effect may be mediated
by induction of COX-2. Aspirin is an inhibitor of COX-2 and has been implicated, with other non-
steroidal anti-inflammatory drugs (NSAIDS) in prevention and treatment of breast cancer. In this
study the in vitro effects of IL-1 and aspirin on growth of MCF-7 human breast cancer cells was
examined.
Methods: MCF-7 cells were treated with various concentrations of IL-1 and aspirin alone and in
combination. Cell growth was assessed by cell number measurement.
Results: Aspirin significantly decreased growth rate in a dose-dependant manner, alone and as a
combined treatment with IL-1 with a maximum reduction in growth rate at 300 mg/ml (P < 0.05).
Treatment with IL-1 alone showed no significant effect on growth rate of MCF-7 cells (P > 0.05).
Conclusion: This study confirms that aspirin suppresses the proliferation rate of MCF-7 cells both
as a single agent and in combination with IL-1. It also suggests that IL-1 alone does not stimulate or
inhibit growth of MCF-7 cells.
Background
Interleukin-1 (IL-1) is a pro-inflammatory cytokine affect-
ing many cell types [1,2]. IL-1 is also present in high levels
at tumor sites where it has been shown to have effects on
the growth and invasiveness of malignant cells by either
inducing growth factors that promote carcinogenesis and
tumor metastasis [3], or by decreasing tumor growth by
direct cytotoxic action [4]. It is thought that expression of
high levels of IL-1 cause broad inflammation which dam-
ages tissue and therefore tumor invasiveness is induced
[1,3]. In addition, IL-1 induce the expression of pro-
inflammatory enzymes mainly Cyclooxygenase 2 (COX-
2), inducible nitric oxide (iNOS), as well as other
cytokines and chemokines. There is also evidence that IL-
1 is secreted by various human tumor cells and in most
cases increases invasive patterns in the tumor cells; antitu-
mor effects were rarely observed [3]. 90% of invasive
breast cancers showed IL-1 expression but to a lesser
extent in benign tumors. Furthermore high levels of IL-1
were associated with other parameters of aggressive
tumors such as estrogen receptor negativity and p53 gene
mutations [3].
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Cyclooxygenase (COX) is an enzyme that catalyses the
conversion of arachidonic acid to important biological
mediators known as prostanoids (prostaglandins, throm-
boxanes and prostacyclin) [5,6]. COX-2 is an inducible
form which is not detected in most healthy tissues but can
be induced in response to a variety of stimuli such as
proinflammatory cytokines (TNF, IL-1), hormones, bacte-
rial polysaccharides and growth factors [5,7,8]. Studies
over recent years have suggested an important role of
COX-2 in tumor formation and progression. Various
human malignancies including breast cancer have shown
increased expression of COX-2. In one study, intermediate
or high levels of COX-2 were detected in 43% of Human
Breast cancer carcinomas and in 62.5% of Ductal Carci-
noma in Situ, and also COX-2 expression was found in
MCF-7 breast cancer cell line induced by HER2 and no
COX-2 proteins in MCF-7 cells alone [9]. Davies et al also
detected COX-2 protein expression in 63 of 89 breast
tumors using immunohistochemical analysis [7]. Costa
and colleagues revealed that COX-2 was expressed in
17.4% of breast carcinomas studied, analyzed by both
immunohistochemistry and western blotting and that
COX-2 was not detected in normal breast tissue. The study
also showed that COX-2 expression was associated with
angiogenesis, lymph node metastasis and apoptosis in
human breast cancer [5].
NSAIDs are widely used in treating symptoms such as
pain and fever associated with inflammation. Epidemio-
logical studies report that these drugs particularly aspirin
may be associated with reduced risk of cancer develop-
ment. Some studies have focused on reduced incidence of
colorectal cancer with NSAIDs use [10], while others have
related to breast cancer. One large prospective cohort
study by Johnson et al reported a trend of decreasing risk
of incident breast cancer among postmenopausal women
with frequent use of aspirin but not with other NSAIDs
[11]. Another case-control study suggested a 40% reduc-
tion in breast cancer incidence in women who reported
daily intake of aspirin and other NSAIDs for at least ten
years [12]. However some studies found no difference in
aspirin intake among women who developed breast can-
cer and those who did not [13]. The main target of
NSAIDs is the COX enzyme and acts by efficiently block-
ing its activity and thus inhibiting COX2. This therefore
inhibits production of several prostaglandins which when
elevated may promote carcinogenesis, through increased
cell proliferation, immune suppression, tumour promo-
tion and facilitate metastasis [11]. Inhibitory effects by
certain COX-2 inhibitors on growth in cancer cell lines
have been shown in some studies. DFU, [5,5-dimethyl-3-
(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-
furanone], a selective COX-2 inhibitor was found to sig-
nificantly reduce tumour growth in mice injected with
MCF-7 cells and also inhibited growth when MCF-7 cells
were cultured for a long period at high drug concentra-
tions [6]. A study by Goel et al found that aspirin inhibited
growth in three colon cancer cell lines [14]. Aspirin and its
parental compound acetylsalicylic acid causes irreversible
inactivation of COX enzyme acting on both COX-1 and -
2. In addition to its anti-inflammatory action, aspirin has
been known to have anti-proliferative effects as well as
anti-apoptotic effects on cancer. This study, therefore
aimed to investigate the interactions between the pro-
inflammatory cytokine IL-1 and anti-inflammatory aspi-
rin on MCF-7 breast cancer cells.
Methods
MCF-7 cells were cultured in DMEM with 10% foetal calf
serum. Cells were trypsinized, and 2.0 × 105 cells/ml
plated per well in multi well plates. After incubation for
twenty four hours, the cells in ten wells from each plate
were treated in duplicate with different concentrations of
IL-1 or aspirin alone and in combination. Viable cells
were counted at 48, 72, 120 and 168 hours and results
recorded. Results were analyzed by one-way analysis of
variance test (ANOVA).
Results
Aspirin inhibited growth of human breast cancer cell line 
MCF-7
Aspirin treatment induced a significant reduction in the
cell proliferation rate of the breast cancer cell line as indi-
cated by the viable cell count for each concentration after
120 hours of incubation (Figure 1). At 300 mg/ml the
growth inhibitory effect of aspirin was most prominent
causing a 70% reduction in cell number compared with
cells incubated with medium alone (P < 0.05). A signifi-
cant reduction of about 20% in proliferation rate was also
Dose- dependant effects of aspirin on the growth rate of  human breast cancer cell line MCF-7 Figure 1
Dose- dependant effects of aspirin on the growth rate of 
human breast cancer cell line MCF-7. Mean ± SD, n = 2.International Seminars in Surgical Oncology 2006, 3:24 http://www.issoonline.com/content/3/1/24
Page 3 of 4
(page number not for citation purposes)
seen at a concentration as low as 30 mg/ml (P < 0.05). The
data establish that aspirin alone can inhibit the growth or
proliferation rate of MCF-7 breast cancer cell line.
No effect of IL-1 on growth of MCF-7 cell line
MCF-7 cells were grown in increasing concentrations of
IL-1, and cell growth determined by counting viable cells
at 24, 48, 72, and 120 hours. No significant decrease in
cell growth was observed with concentrations of 5.0-0.1
ng/ml IL-1 compared to the control group after 68 hours
of incubation (Figure 2). Therefore this evidence suggests
that IL-1 has no significant effect on the growth rate of
MCF-7 breast cancer cells alone.
No effect of IL-1 on aspirin-mediated inhibition of 
proliferation of MCF-7 cells
MCF-7 breast cancer cells were exposed to 5 ng/ml IL-1
followed by three concentrations of aspirin, incubated
and viable cells counted for a period of 72 hours. At 300
mg/ml aspirin, a significant reduction in proliferation rate
of about 70% was observed (p < 0.05) compared to the
control group, and was also significantly different from
the other treatment concentrations after 72 hours (Figure
3). Maximal effect of aspirin inhibition was observed after
120 hours at a dose of 300 mg/ml (p < 0.05). Significant
inhibition effects were also seen at 3 mg/ml and 30 mg/ml
after 120 hours (p < 0.05).
These findings suggest that aspirin is capable of inhibiting
growth rate of MCF-7 cells even when combined with IL-
1.
Discussion
In this study, the effects of the pro-inflammatory cytokine
IL-1 and aspirin, a COX-2 inhibitor, on the growth of
MCF-7 breast carcinoma cell line in vitro were examined.
No effect of IL-1 alone on cell proliferation was seen. This
reflects the results of previous studies where, IL-1 alone
did not induce a significant effect, but an effect was seen
only when the cancer cells were cultured with growth fac-
tors before treatment with IL-1. The growth of MCF-7
breast cancer cells is controlled by a number of factors
such as estrogen and growth factors [15]. Two previous
studies showed that IL-1 inhibited growth effects of MCF-
7 cells that were stimulated by growth factors, insulin- like
growth factor-I (IGF-I) and insulin by targeting and inhib-
iting the insulin growth factor receptors [4,15]. Both stud-
ies also showed that IL-1 alone did not directly induce cell
death or impair cell growth. Aspirin and other related
NSAIDs have been shown to have chemopreventive activ-
ity on cancer [11] as well as inhibiting growth and/or for-
mation of tumors [6] through targeting action of COX-2,
an enzyme responsible for production of prostaglandins.
COX-2 has been implicated in the development and pro-
gression of several tumors. The known mechanisms of the
activity of aspirin and other COX-2 inhibitors involve
decrease in tumor cell activity and/or proliferation
through apoptosis and decreased production of prostag-
landins. Prostaglandins such as PGE2 are known to sup-
press the immune system through down- regulation of
lymphokines, proliferation of T and B cells, as well as
cytotoxic activity of natural killer cells [16]. In the present
study, aspirin showed a markedly response by directly
inhibiting growth of the MCF-7 cells, with a maximum
effect at a dose concentration of 300 mg/ml. It has been
known that COX-2 enzyme is present in many inflamed
and neoplastic tissues and that it can be induced in
response to variety of stimuli such as growth factors (Vas-
cular Endothelial Growth Factor VEGF, Epidermal
Dose and time- dependant effects of aspirin on the growth of  MCF-7 Breast cancer cell line after treatment with IL-1 Figure 3
Dose and time- dependant effects of aspirin on the growth of 
MCF-7 Breast cancer cell line after treatment with IL-1. Cells 
were treated with 5 ng/ml IL-1, exposed to various concen-
trations of aspirin and incubated for up to 120 hours. Mean ± 
SD, n = 2.
Growth curve for MCF-7 breast cancer cell line exposed to  different concentrations of the cytokine IL-1 and incubated  for up to 168 hours Figure 2
Growth curve for MCF-7 breast cancer cell line exposed to 
different concentrations of the cytokine IL-1 and incubated 
for up to 168 hours. Cell counts were performed at 24 h, 48 
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Growth Factor EGF, Fibroblast Growth Factor FGF) and
pro-inflammatory cytokines (IL-1, TNF) [16]. However, in
the present study, no effect of IL-1 on the growth-inhibi-
tory properties of aspirin were seen, and suggests that
aspirin mediates the effect directly on breast cancer cells
and not through anti-inflammatory pathways.
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